No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Hao LiuMark D'AlesioSamer AlMasriAbdulrahman HammadAnnissa DesilvaSteven LebowitzCaroline RieserEishan AshwatErica HamptonHussein KhachfeMckenna LaffeyAatur SinghiNathan BaharyKenneth LeeAmer ZureikatAlessandro PanicciaPublished in: HPB : the official journal of the International Hepato Pancreato Biliary Association (2023)
CA19-9 response to NAC may serve as the marker for effective NAC. These findings warrant validation in a multi-institutional study.